Table 3.
Correlation between CK20 mRNA detection in blood of esophageal carcinoma patients and clinical parameters.
| Variable | Detection of CK20 mRNA in Blood (n = 74) | Correlation χ2-Test (p-Value) |
|||
|---|---|---|---|---|---|
| Total | Positive (%) | Negative (%) | |||
| Gender | Female | 13 | 7 (53.85%) | 6 (46.15%) | 0.152 |
| Male | 61 | 20 (32.79%) | 41 (67.21%) | ||
| UICC-stage (n = 70) |
I | 16 | 5 (31.25%) | 11 (68.75%) | 0.447 |
| II | 26 | 9 (34.62%) | 17 (65.38%) | ||
| III | 18 | 6 (33.33%) | 12 (66.67%) | ||
| IV | 10 | 6 (60%) | 4 (40%) | ||
| T-category (n = 71) |
I | 18 | 5 (27.78%) | 13 (72.22%) | 0.439 |
| II | 22 | 7 (31.82%) | 15 (68.18%) | ||
| III | 30 | 14 (46.67%) | 16 (53.33%) | ||
| IV | 1 | 0 | 1 (100%) | ||
| N-category (n = 74) |
0 | 33 | 13 (39.39%) | 20 (60.61%) | 0.641 |
| I | 41 | 14 (34.15%) | 27 (65.85%) | ||
| M-category (n = 73) | 0 | 63 | 21 (33.33%) | 42 (66.67%) | 0.105 |
| I | 10 | 6 (60%) | 4 (40%) | ||
| Neo-adjuvant therapy | Yes | 31 | 12 (38.71%) | 19 (61.29%) | 0.736 |
| No | 43 | 15 (34.88%) | 28 (65.12%) | ||
| Relapse | Yes | 34 | 15 (44.12%) | 19 (55.88%) | 0.209 |
| No | 40 | 12 (30%) | 28 (70%) | ||
| Tumor type (histological) (n = 73) |
Adenocarcinoma SCC | 38 | 10 (26.32%) | 28 (73.68%) | 0.084 |
| 35 | 16 (45.71%) | 19 (54.29%) | |||